Xenon Pharmaceuticals Inc.
DE ˙ DB ˙ CA98420N1050
45,60 € ↑1,00 (2,24%)
2026-06-04
AKTIENPREIS
SecurityDE:XP0 / Xenon Pharmaceuticals Inc.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership527,783 shares
Latest Disclosed Value $ 30,690,581
Northern Trust Corp reports 20.30% increase in ownership of XP0 / Xenon Pharmaceuticals Inc.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 527,783 shares of Xenon Pharmaceuticals Inc. (DE:XP0) valued at $25,333,584 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 438,714 shares of Xenon Pharmaceuticals Inc.. This represents a change in shares of 20.30% during the quarter. The current value of the position is $24,066,905 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F XENON PHARMACEUTICALS COM 98420N105 527,783 89,069 20.30 30,691 56.08 0.0008
2026-02-17 2025-12-31 13F XENON PHARMACEUTICALS COM 98420N105 438,714 -59,433 -11.93 19,663 -1.68 0.0025
2025-11-14 2025-09-30 13F XENON PHARMACEUTICALS COM 98420N105 498,147 8,207 1.68 20,001 30.42 0.0026
2025-08-13 2025-06-30 13F XENON PHARMACEUTICALS COM 98420N105 489,940 408,916 504.69 15,335 464.20 0.0021
2025-05-13 2025-03-31 13F XENON PHARMACEUTICALS COM 98420N105 81,024 15,241 23.17 2,718 5.43 0.0004
2025-02-14 2024-12-31 13F XENON PHARMACEUTICALS COM 98420N105 65,783 22,377 51.55 2,579 50.94 0.0004
2024-11-13 2024-09-30 13F XENON PHARMACEUTICALS COM 98420N105 43,406 -3,446 -7.36 1,709 -6.46 0.0003
2024-08-14 2024-06-30 13F XENON PHARMACEUTICALS COM 98420N105 46,852 -1,618 -3.34 1,827 -12.46 0.0003
2024-05-14 2024-03-31 13F XENON PHARMACEUTICALS COM 98420N105 48,470 -13,501 -21.79 2,087 -26.91 0.0004
2024-02-13 2023-12-31 13F XENON PHARMACEUTICALS COM 98420N105 61,971 -7,196 -10.40 2,854 20.83 0.0005
2023-11-13 2023-09-30 13F XENON PHARMACEUTICALS COM 98420N105 69,167 3,684 5.63 2,363 -6.31 0.0005
2023-08-11 2023-06-30 13F XENON PHARMACEUTICALS COM 98420N105 65,483 4,480 7.34 2,521 15.48 0.0005
2023-05-15 2023-03-31 13F XENON PHARMACEUTICALS COM 98420N105 61,003 786 1.31 2,183 -8.05 0.0004
2023-02-13 2022-12-31 13F XENON PHARMACEUTICALS COM 98420N105 60,217 9,326 18.33 2,374 29.23 0.0005
2022-11-14 2022-09-30 13F XENON PHARMACEUTICALS COM 98420N105 50,891 2,895 6.03 1,837 25.82 0.0004
2022-08-12 2022-06-30 13F XENON PHARMACEUTICALS COM 98420N105 47,996 3,220 7.19 1,460 6.73 0.0003
2022-05-13 2022-03-31 13F XENON PHARMACEUTICALS COM 98420N105 44,776 -5,820 -11.50 1,368 -13.42 0.0002
2022-02-08 2021-12-31 13F XENON PHARMACEUTICALS COM 98420N105 50,596 12,746 33.68 1,580 172.88 0.0003
2021-11-15 2021-09-30 13F XENON PHARMACEUTICALS COM 98420N105 37,850 -6,871 -15.36 579 -30.41 0.0001
2021-08-13 2021-06-30 13F XENON PHARMACEUTICALS COM 98420N105 44,721 -5,841 -11.55 832 -7.96 0.0001
2021-05-12 2021-03-31 13F XENON PHARMACEUTICALS COM 98420N105 50,562 3,940 8.45 904 26.08 0.0002
2021-02-11 2020-12-31 13F XENON PHARMACEUTICALS COM 98420N105 46,622 -15,731 -25.23 717 3.91 0.0001
2020-11-16 2020-09-30 13F XENON PHARMACEUTICALS COM 98420N105 62,353 718 1.16 690 -10.62 0.0002
2020-08-14 2020-06-30 13F XENON PHARMACEUTICALS COM 98420N105 61,635 3,036 5.18 772 16.27 0.0002
2020-05-14 2020-03-31 13F XENON PHARMACEUTICALS COM 98420N105 58,599 14,456 32.75 664 14.68 0.0002
2020-02-14 2019-12-31 13F XENON PHARMACEUTICALS COM 98420N105 44,143 6,507 17.29 579 70.80 0.0001
2019-11-13 2019-09-30 13F XENON PHARMACEUTICALS COM 98420N105 37,636 0 0.00 339 -8.63 0.0001
2019-08-13 2019-06-30 13F XENON PHARMACEUTICALS COM 98420N105 37,636 13,434 55.51 371 50.81 0.0001
2019-05-13 2019-03-31 13F XENON PHARMACEUTICALS COM 98420N105 24,202 11,956 97.63 246 219.48 0.0001
2019-02-12 2018-12-31 13F XENON PHARMACEUTICALS COM 98420N105 12,246 1,948 18.92 77 -43.38 0.0000
2018-11-14 2018-09-30 13F XENON PHARMACEUTICALS COM 98420N105 10,298 10,298 136 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.